Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder. For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).
Seth Lederman is a physician, scientist and specialty pharmaceuticals entrepreneur. Prior to founding Tonix, Dr. Lederman co-founded and was a managing partner of Konanda Pharma Partners, LLC and Konanda Pharma Fund I, LP. He co-founded and served as director and chairman of its wholly-owned operating companies Validus and Fontus Pharmaceuticals Inc., which market Equetro® (carbamazepine – Extended Release), Marplan® (isocarboxazid) and Rocaltrol® (calcitriol). In 2000 Dr. Lederman founded Targent Pharmaceuticals to develop late-stage oncology drugs including pure-isomer levofolinic acid, which was sold to Spectrum Pharmaceuticals and is now FDA-approved and marketed as Fusilev® for colorectal cancer. In 1998 Dr. Lederman co-founded Vela Pharmaceuticals, which developed several drugs for central nervous system disorders, including VLD-cyclobenzaprine.
Dr. Lederman served as an Associate Professor at Columbia University from 1996 until retiring on April 13, 2017. He joined the faculty of Columbia University's College of Physicians and Surgeons in 1985, became Assistant Professor of Medicine in 1988, and Associate Professor with tenure in 1996 and Director of the Laboratory of Molecular Immunology in 1997. From 1988 to 2002, Dr. Lederman directed basic science research at Columbia in molecular immunology, infectious diseases and the development of therapeutics for autoimmune diseases. Dr. Lederman is author of numerous scientific articles, and inventor of technologies recognized by a number of issued patents. His fundamental work on the CD40-Ligand (CD154) elucidated the molecular basis of T cell helper function and has led to the development of therapeutic candidates for autoimmune diseases and organ transplant rejection in collaboration with Biogen-IDEC and CellTech/UCB. The successful defense of his CD154 patents has led to important precedents in defining the relationship of therapeutics and molecular targets. In collaboration with Prof. David Baltimore (then at Rockefeller University and later MIT), Dr. Lederman identified and functionally characterized the CD40 signaling molecule, TRAF-3. His early work on HIV contributed to the understanding of how the V3 loop of HIV gp120 was involved in fusion with CD4 cell membranes, an early and essential event in viral entry and infection. In addition to his research, Dr. Lederman served as attending physician in the Edward Daniels Arthritis and Autoimmunity Clinic on the Medical Service at Columbia Presbyterian Hospital from 1988-1996.
Dr. Lederman earned an AB from Princeton in Chemistry cum laude in 1979 and an MD from Columbia University's College of Physicians and Surgeons in 1983. Dr. Lederman trained in internal medicine and rheumatology at Columbia's Presbyterian Hospital. He was an NIH Physician-Scientist 1985-1990 at Columbia.
Mr. Davidson is a managing partner of Labrador Ventures, a venture capital firm focusing on technology companies, as well as chairman and a co-founder of Sonen Capital, an asset management firm. He has been involved in investing in early-stage companies for over 20 years. Mr. Davidson founded and served as CEO of Combion, Inc., which was acquired by Incyte Pharmaceuticals, Inc. (NASDAQ: INCY). He also served as President of Alkermes, Inc. (NASDAQ: ALKS), a biotechnology company focused on drug delivery where he managed the development of the company from concept stage through the initiation of human clinical trials prior to the company's initial public offering. Mr. Davidson worked previously for MCI Communications and Warner Communications.
Mr. Davidson received an AB and an MBA from Harvard.
Mr. Grace is Managing Partner of Apollo Philanthropy Partners, LLC, a New York-based strategic consulting firm serving private philanthropists and the nonprofit sector. Mr. Grace is an experienced senior executive with expertise in strategic planning, general management, finance, operations, supply chain management and the not-for-profit sector. Mr. Grace has experience with both overseas and domestic companies, ranging in size from Fortune 50 companies to start-ups. Since 1996, Mr. Grace has been President of both MLP Capital, Inc., a private investment firm, and GMS Timber Co, a forestry management company. During this same period, he has also overseen a number of non-profit entities. In this latter connection, Mr. Grace is responsible for governance, investment management, asset allocation, and the finance, accounting, tax and legal functions. Previously, Mr. Grace served as President and CEO of Kingdom Group, LLC, a provider of Compressed Natural Gas (CNG) fueling stations for alternative fuel vehicles, and COO and CFO of C3 Communications, Inc. an in-store marketing/promotion company. Over the period 1977-1995, Mr. Grace served in a variety of roles at W.R. Grace & Co. including Grace Logistics, Inc., a $35 million operating company with responsibility for Grace's $5.0 billion in annual supply chain activities (President, 1991-1995); Kascho GmbH, a $140 million chocolate manufacturer (Managing Director & Chief Financial Officer, 1988-1991); Grace Cocoa, a $700 million global cocoa products manufacturer (Project Manager, 1986-1988); the Financial Planning & Analysis Division of W. R. Grace & Co. (Group Manager, 1982-1986); Chemed Corporation, a $350 million specialty chemicals manufacturer and health care provider (Assistant to the President, 1980-1982); Omnicare, Inc., a $70 million provider of hospital pharmacy services (Project Manager, 1979-1980). Mr. Grace is a Director of Chemed Corporation (NYSE: CHE), serving on both Audit and Nominating Committees. Mr. Grace is also Chairman of the Board of the Grace Institute and Chairman of the Board of KickStart International, in addition to serving as a board member or officer of a number of other non-profit entities.
Mr. Grace was a Liberal Arts major at the University of Notre Dame and graduated from Columbia University's Graduate School of Business with an M.B.A. in Finance.
Dr. Landry is the Samuel Bard Professor and Chair of the Department of Medicine (tenured) at Columbia University's College of Physicians and Surgeons. Dr. Landry also serves as Director of the Division of Experimental Therapeutics. Dr. Landry was a co-founder (with Dr. Lederman, above)of Vela Pharmaceuticals, which developed several drugs for central nervous system disorders, including very low dose (VLD)-cyclobenzaprine for fibromyalgia syndrome. At Columbia, Dr. Landry developed the first artificial enzyme to degrade cocaine and his report in Science was voted one of top 25 papers in the world for 1993 by the American Chemical Society. His discovery that vasopressin can be used to treat shock fundamentally changed intensive care medicine after an international randomized prospective trial supported his published findings and demonstrated a reduction of mortality in moderately severe septic shock. Dr. Landry is a leader in the development and ethics of embryonic stem cell research and served as a member of the President's Council on Bioethics during the George W. Bush administration. In 1991, he established his laboratory at Columbia University to investigate medical applications of artificial enzymes and in 1998 founded the Division of Experimental Therapeutics. The Division focuses on novel therapeutics for intractable problems such as cocaine addiction, nerve gas intoxication and vasodilatory shock.
Dr. Landry graduated from Lafayette College, completed his Ph.D. in organic chemistry under Nobel laureate R.B. Woodward at Harvard University in 1979 and then obtained his M.D. degree from Columbia University's College of Physicians and Surgeons in 1983. After residency in Internal Medicine at the Massachusetts General Hospital, he returned to Columbia University as an NIH Physician-Scientist, 1985-1990.
Dr. Mario is a former Deputy Chairman and Chief Executive of Glaxo Holdings plc and a former Chairman and Chief Executive Officer of ALZA Corporation. Dr. Mario served in management at a number of drug companies before being named in 1989 Chief Executive of Glaxo, then the second-largest drug company in the world. During Dr. Mario's tenure, Glaxo brought five major new products to market and saw sales and profits increase by 15% annually. Later Dr. Mario led pioneering drug delivery technology company ALZA until selling it to Johnson & Johnson in 2001. He subsequently served as Chairman and Chief Executive Officer of Reliant Pharmaceuticals, where he led the commercialization of LOVAZA®, the first and only prescription omega-3 medication clinically proven to dramatically reduce very high triglycerides. Dr. Mario serves as a director of publicly-traded healthcare companies: Boston Scientific Corporation, Capnia Inc., Celgene Corporation, Chimerix Inc. (Chairman), Kindred Biosciences Inc., and XenoPort Inc. In addition to his current and past service on a number of corporate boards, Dr. Mario is active in numerous educational and healthcare organizations. He is Chairman of the American Foundation for Pharmaceutical Education and is past Chairman of the Duke University Health System.
Dr. Mario earned a BS in pharmacy at Rutgers and his MS and PhD in physical sciences at the University of Rhode Island (URI). He holds honorary doctorates from URI and Rutgers, the latter of which in 2001 renamed its pharmacy school the Ernest Mario School of Pharmacy. In 2007 he was awarded the Remington Medal by the American Pharmacists' Association, pharmacy's highest honor.
Mr. Mather served as a Managing Director at Janney Capital Markets from 2009 to 2015. He was most recently Co-Head of the Equity Capital Markets Group where he was responsible for public offerings, private placements, PIPES, registered directs and other financings. Previously, Mr. Mather served as Managing Director at Jefferies and, as Head of the Structured Equity Group, was responsible for the origination and execution of private placements for private companies, registered direct and PIPE offerings for public companies and special purpose acquisition companies. Prior to Jefferies, he was at Cowen and Company for ten years where he was a Managing Director and led the Private Equity Group. Before Cowen, Mr. Mather held senior investment banking and investment positions at Smith Barney Inc. and Prudential Investment Corporation. Mr. Mather has completed advisory and capital raising assignments for more than 100 companies.
Mr. Mather received an AB in History from Brown University and an MBA in Finance from the Wharton School at the University of Pennsylvania. He is a Chartered Financial Analyst (CFA).
Mr. Rhodes is the President and CEO of the New York State Energy Research and Development Authority (NYSERDA), a public benefit corporation which offers information and analysis, technical expertise and funding to help New Yorkers increase energy efficiency and reduce reliance on fossil fuels. Mr. Rhodes works with public and private partners to expand investment and innovation in energy to drive New York's clean energy economy and stimulate economic activity. Mr. Rhodes is a former partner at Booz Allen Hamilton (1987-2002) where he led significant work in strategy and commercial operations globally for clients in biotech and pharmaceuticals. He had a particular focus on business optimization, including clinical development strategies for new and existing molecules, market repositioning and commercial operations for established drugs, and business development strategies to enhance drug portfolios and pipelines. Recently Mr. Rhodes served as Senior Advisor to Good Energies (2007-2010), a private investment firm focused on renewable energy and energy efficiency, where he developed strategy, supported portfolio companies and served on the management team. Mr. Rhodes serves on the board of several non-profit organizations, including the Hospital for Joint Diseases, New York, and the American Federation for Aging Research, New York. Mr. Rhodes is a graduate of Princeton University (1979) and the Yale School of Management (1987).
Dr. Saks is former CEO of Jazz Pharmaceuticals (NASDAQ: JAZZ), which he co-founded in 2003. At Jazz, Dr. Saks was responsible for the commercialization of Xyrem® (sodium oxybate) for cataplexy and excessive daytime sleepiness associated with narcolepsy. Dr. Saks also designed and led the effort to develop sodium oxybate as a treatment for fibromyalgia. Although the program to develop sodium oxybate as a treatment for this indication was abandoned in 2011, robust efficacy in treating pain and other key symptoms was demonstrated. Sodium oxybate has also been shown to significantly improve disordered sleep, a mechanism targeted by Tonix's lead program for fibromyalgia. From 2001 until he joined Jazz, Dr. Saks was company group chairman of ALZA Corporation and a member of the Johnson & Johnson Pharmaceuticals Operating Committee. Prior to its acquisition by Johnson & Johnson (NYSE: JNJ) in 2001, from 1992 until 2001 Dr. Saks held executive positions at ALZA including Group Vice President, where he was responsible for clinical, regulatory and commercial activities. At ALZA Dr. Saks played an important role in developing Concerta®, a new formulation of methylphenidate for attention deficit hyperactivity disorder.
Prior to joining ALZA, Dr. Saks held clinical research and development management positions with Schering-Plough, Xoma and Genentech. Dr. Saks formerly served as a scientific advisor to ArQule Pharmaceuticals (NASDAQ: ARQL), CMEA Ventures and ProQuest Investments. Dr. Saks served as a Director of Cougar Biotechnology, which was acquired by Johnson & Johnson in 2009, and as a Director of Trubion Pharmaceuticals, which was acquired by Emergent BioSolutions in 2010. From April 2011 until February 2012, Dr. Saks served as interim Chief Medical Officer of Threshold Pharmaceuticals (NASDAQ: THLD).
Dr. Saks received his Bachelor of Science degree in biology and his Doctor of Medicine degree from the University of Illinois. From 1987 to 2000 he was Assistant Clinical Professor of Medicine in the oncology division of the Department of Medicine at the University of California, San Francisco.